---
title: "Otezla (apremilast) in plaque psoriasis: Clinical trials questions"
description: "Clinical trials questions on Otezla (apremilast) in plaque psoriasis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Study results. Questions: How effective is Otezla vs placebo for moderate to severe plaque psoriasis at 16 weeks? How were the Otezla ESTEEM plaque psoriasis trials designed? Does Otezla work for mild to moderate plaque psoriasis vs placebo (ADVANCE)? Does Otezla relieve plaque psoriasis itch vs placebo at 16 weeks? 4 further questions follow. 8 questions quoted from 6 sources."
canonical: "https://www.evicenter.com/medical-information/otezla--plaque-psoriasis/clinical-trials"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Otezla (apremilast) in plaque psoriasis: Clinical trials questions

Manufacturer: Amgen Inc.  
Prescribing information: [Otezla](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf)

Questions that apply to every indication of Otezla are on [Otezla (apremilast), all indications](https://www.evicenter.com/medical-information/otezla).

## Study results

<a id="otezla-esteem-results"></a>

### How effective is Otezla vs placebo for moderate to severe plaque psoriasis at 16 weeks?

Applies to: Moderate to severe plaque psoriasis in adults who are candidates for phototherapy or systemic therapy (ESTEEM 1 and ESTEEM 2; PSOR-1 and PSOR-2 in the label)

> “In ESTEEM 1, 33% of patients taking Otezla (n=562) achieved PASI-75 response vs 5% with placebo (n=282) at week 16 (P<0.0001; primary endpoint; LOCF; FAS) <sup>5,6</sup>
> In ESTEEM 2, 29% of patients taking Otezla (n=274) achieved PASI-75 response vs 6% with placebo (n=137) at week 16 (P<0.001; primary endpoint) <sup>7</sup>”

Source: [OTEZLA: PsO Efficacy Overview, captured 2026-11-13](https://www.otezlapro.com/plaque-psoriasis/efficacy/#:~:text=In%20ESTEEM%201%2C%2033%25%20of,week%2016%20%28P%3C0.001%3B%20primary%20endpoint%29)

> “Trial PSOR-1 enrolled 844 subjects and Trial PSOR-2 enrolled 413 subjects. In both trials, subjects were 
> randomized 2:1 to OTEZLA 30 mg twice daily (BID) or placebo for 16 weeks. Both trials assessed the 
> proportion of subjects who achieved PASI-75 at Week 16 and the proportion of subjects who achieved an 
> sPGA score of clear (0) or almost clear (1) at Week 16.”

Source: [OTEZLA: Prescribing information, page 22, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=22)

> “Table 8. Clinical Response at Week 16 in Adults with Moderate to Severe Plaque Psoriasis in Trials 
> PSOR-1 and PSOR-2 
>
> Trial PSOR-1 
> Trial PSOR-2 
> Placebo 
> OTEZLA 
> 30 mg BID 
> Placebo 
> OTEZLA 
> 30 mg BID<sup>d</sup> 
> N<sup>a</sup> 
> N = 282 
> N = 562 
> N = 137 
> N = 274 
> PASI<sup>b</sup> -75, n (%) 
> 15 (5.3) 
> 186 (33.1) 
> 8 (5.8) 
> 79 (28.8) 
> sPGA<sup>c</sup> of Clear or 
> Almost Clear, n (%) 
> 11 (3.9) 
> 122 (21.7) 
> 6 (4.4) 
> 56 (20.4) 
> <sup>a</sup>  N is number of randomized and treated subjects. 
> <sup>b</sup>  PASI = Psoriasis Area and Severity Index. 
> <sup>c</sup>  sPGA = Static Physician Global Assessment. 
> <sup>d</sup>  BID = twice daily.”

Source: [OTEZLA: Prescribing information, page 22, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=22)

Note: The Otezla HCP site names the trials ESTEEM 1 (N=844) and ESTEEM 2 (N=413); the Prescribing Information names the same enrollments PSOR-1 and PSOR-2. Table 8 columns are placebo and OTEZLA 30 mg twice daily for PSOR-1, then placebo and OTEZLA 30 mg twice daily for PSOR-2.

<a id="otezla-esteem-design"></a>

### How were the Otezla ESTEEM plaque psoriasis trials designed?

Applies to: Moderate to severe plaque psoriasis in adults who are candidates for phototherapy or systemic therapy (ESTEEM 1 and ESTEEM 2; PSOR-1 and PSOR-2 in the label)

> “Evaluated in 2 multicenter, double-blind, placebo-controlled trials of similar design. Patients with moderate to severe plaque psoriasis (N=1257) were randomized 2:1 to Otezla 30 mg BID or placebo for 16 weeks after a 5-day titration <sup>1</sup>
> At week 16, all patients originally assigned to placebo transitioned to Otezla 30 mg BID. At week 32, some patients originally randomized to Otezla were, based on clinical response, re-randomized to Otezla or placebo. Those re-randomized to placebo restarted Otezla 30 mg BID at loss of response, but no later than at week 52 <sup>2,3</sup>”

Source: [OTEZLA: ESTEEM Study Design for PsO l, captured 2026-11-13](https://www.otezlapro.com/plaque-psoriasis/study-design/esteem/#:~:text=Evaluated%20in%202%20multicenter%2C%20double%2Dblind%2C,later%20than%20at%20week%2052)

> “Patients entering a long-term extension phase could be treated through 5 years <sup>2,3</sup>”

Source: [OTEZLA: ESTEEM Study Design for PsO l, captured 2026-11-13](https://www.otezlapro.com/plaque-psoriasis/study-design/esteem/#:~:text=Patients%20entering%20a%20long%2Dterm%20extension%20phase%20could%20be%20treated%20through%205%20years)

> “Primary endpoint: <sup>2,3</sup>
> The proportion of patients who achieved PASI-75 at week 16”

Source: [OTEZLA: ESTEEM Study Design for PsO l, captured 2026-11-13](https://www.otezlapro.com/plaque-psoriasis/study-design/esteem/#:~:text=Primary%20endpoint%3A,achieved%20PASI%2D75%20at%20week%2016)

<a id="otezla-advance-mild-moderate"></a>

### Does Otezla work for mild to moderate plaque psoriasis vs placebo (ADVANCE)?

Applies to: Mild to moderate plaque psoriasis in adults with an inadequate response or intolerance to topical therapy (ADVANCE; PSOR-4 in the label)

> “In ADVANCE, 22% of patients taking Otezla (n=297) achieved an sPGA score of 0 (clear) or 1 (almost clear) and a ≥2-point reduction from baseline vs 4% with placebo (n=298) at week 16 (P<0.0001; primary endpoint; ITT population) <sup>1,2</sup>”

Source: [OTEZLA: PsO Efficacy Overview, captured 2026-11-13](https://www.otezlapro.com/plaque-psoriasis/efficacy/#:~:text=In%20ADVANCE%2C%2022%25%20of%20patients,%28P%3C0.0001%3B%20primary%20endpoint%3B%20ITT%20population%29)

> “A multicenter, randomized, double-blind, placebo-controlled trial (PSOR-4 [NCT03721172]) was 
> conducted in 595 adult subjects with mild to moderate plaque psoriasis (BSA involvement of 2-15%, 
> sPGA score of 2-3 [mild or moderate disease], and PASI score of 2-15). Enrolled subjects had an 
> inadequate response or were intolerant to at least one topical therapy and had not received prior biologic 
> therapy. Subjects were allowed to use unmedicated emollients for lesions on non-scalp areas of the body 
> and non-medicated shampoos for lesions on the scalp. 
>
> Subjects were randomized 1:1 to receive either OTEZLA 30 mg twice daily (n = 297) or placebo twice 
> daily (n = 298) for 16 weeks. At Week 16, the placebo group was switched to receive OTEZLA and the 
> OTEZLA group remained on drug through Week 32. The primary endpoint was the proportion of subjects 
> who achieved an sPGA response (defined as an sPGA score of clear [0] or almost clear [1] with at least a 
> 2-point reduction from baseline) at Week 16.”

Source: [OTEZLA: Prescribing information, page 27, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=27)

> “Subjects with mild disease (sPGA = 2 at baseline) were 
> required to be clear (sPGA = 0) to achieve an sPGA response.”

Source: [OTEZLA: Prescribing information, page 27, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=27)

Note: The Otezla HCP site names the trial ADVANCE; the Prescribing Information names it PSOR-4 (595 adults randomized to OTEZLA 30 mg twice daily or placebo).

<a id="otezla-itch"></a>

### Does Otezla relieve plaque psoriasis itch vs placebo at 16 weeks?

Applies to: Plaque psoriasis in adults who are candidates for phototherapy or systemic therapy

> “Table 12. Efficacy Results at Week 16 in Adults with Mild to Moderate Plaque Psoriasis in Trial 
> PSOR-4 
> Trial PSOR-4 
> Placebo 
> OTEZLA 
> 30 mg 
> twice 
> daily 
> Treatment  
> Difference<sup>a,b</sup> 
> (95% CI<sup>c</sup>) 
> Number of Subjects Randomized 
> N = 298 
> N = 297”

Source: [OTEZLA: Prescribing information, page 27, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=27)

> “Number of Subjects with Baseline Whole Body Itch NRS 
> Score ≥ 4 
> N = 249 
> N = 253 
>
> Whole Body Itch NRS Response<sup>e</sup> 
> 18.6% 
> 43.2% 
> 24.7% 
> (16.5%, 32.8%)”

Source: [OTEZLA: Prescribing information, page 27, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=27)

> “<sup>e</sup>  Whole Body Itch NRS score reduction of ≥ 4-points from baseline.”

Source: [OTEZLA: Prescribing information, page 28, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=28)

> “Table 9. Efficacy Results at Week 16 in Adults with Plaque Psoriasis of the Scalp in Trial PSOR-3 
>
> Trial PSOR-3 
>
> Placebo 
> OTEZLA  
> 30 mg  
> twice 
> daily 
> Treatment  
> Difference<sup>a,b</sup> 
> (95% CI<sup>c</sup>) 
> Number of subjects randomized 
> N = 102 
> N = 201”

Source: [OTEZLA: Prescribing information, page 23, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=23)

> “Number of subjects with baseline Whole Body Itch NRS 
> Score ≥ 4 
> N = 94 
> N = 185 
>
> Whole Body Itch NRS response 
> 22.5% 
> 45.5% 
> 23.0%  
> (11.5%, 
> 34.6%) 
> Number of subjects with baseline Scalp Itch NRS Score ≥ 4 
> N = 90 
> N = 175 
>
> Scalp Itch NRS response 
> 21.1% 
> 47.1% 
> 26.2%  
> (13.9%, 
> 38.5%)”

Source: [OTEZLA: Prescribing information, page 23, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=23)

Note: Columns in both tables are placebo, OTEZLA 30 mg twice daily, and the treatment difference with its 95% CI. Trial PSOR-4 (ADVANCE on the Otezla HCP site) enrolled adults with mild to moderate plaque psoriasis; Trial PSOR-3 (STYLE) enrolled adults with moderate to severe plaque psoriasis of the scalp. Both itch responses are a reduction of at least 4 points from baseline, among subjects with a baseline score of at least 4.

<a id="otezla-scalp-style"></a>

### How effective is Otezla vs placebo for moderate to severe scalp psoriasis (STYLE)?

Applies to: Moderate to severe plaque psoriasis of the scalp in adults (STYLE; PSOR-3 in the label)

> “STYLE study design: A Phase 3, multicenter, randomized, double-blind, placebo-controlled study of 303 adult moderate to severe plaque psoriasis patients with moderate to severe plaque psoriasis of the scalp. <sup>1</sup>”

Source: [OTEZLA: PsO Efficacy Overview, captured 2026-11-13](https://www.otezlapro.com/plaque-psoriasis/efficacy/#:~:text=STYLE%20study%20design%3A%20A%20Phase,plaque%20psoriasis%20of%20the%20scalp.)

> “In STYLE, 43% of patients taking Otezla (n=201) achieved a significant improvement in ScPGA response vs 14% with placebo (n=102) at week 16 (P<0.0001; primary endpoint; ITT population; MI analysis) <sup>6</sup>”

Source: [OTEZLA: PsO Efficacy Overview, captured 2026-11-13](https://www.otezlapro.com/plaque-psoriasis/efficacy/#:~:text=In%20STYLE%2C%2043%25%20of%20patients,endpoint%3B%20ITT%20population%3B%20MI%20analysis%29)

> “Subjects were randomized 2:1 to receive either OTEZLA 30 mg twice daily (n = 201) or placebo twice 
> daily (n = 102) for 16 weeks. The primary endpoint was the proportion of subjects who achieved an 
> ScPGA response at Week 16 (defined as ScPGA score of clear [0] or almost clear [1] with at least a 
> 2-point reduction from baseline at Week 16).”

Source: [OTEZLA: Prescribing information, page 23, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=23)

> “Table 9. Efficacy Results at Week 16 in Adults with Plaque Psoriasis of the Scalp in Trial PSOR-3 
>
> Trial PSOR-3 
>
> Placebo 
> OTEZLA  
> 30 mg  
> twice 
> daily 
> Treatment  
> Difference<sup>a,b</sup> 
> (95% CI<sup>c</sup>) 
> Number of subjects randomized 
> N = 102 
> N = 201 
>
> ScPGA response<sup>d</sup> 
> 13.7% 
> 43.3% 
> 29.6%  
> (19.5%, 
> 39.7%)”

Source: [OTEZLA: Prescribing information, page 23, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=23)

> “<sup>d</sup>  ScPGA score of clear [0] or almost clear [1] with at least a 2-point reduction from baseline.”

Source: [OTEZLA: Prescribing information, page 23, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=23)

Note: The Otezla HCP site names the trial STYLE; the Prescribing Information names it PSOR-3. Table 9 columns are placebo, OTEZLA 30 mg twice daily, and the treatment difference with its 95% CI.

<a id="otezla-sprout-children"></a>

### How effective is Otezla vs placebo for children with plaque psoriasis (SPROUT)?

Applies to: Moderate to severe plaque psoriasis in pediatric patients 6 years of age and older who are candidates for phototherapy or systemic therapy and weigh at least 20 kg (OTEZLA) or at least 50 kg (OTEZLA XR)

> “SPROUT study design: A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety of Otezla in 245 pediatric patients whose ages ranged from 6 to 17 years old and weighing at least 20 kg, with moderate to severe plaque psoriasis. <sup>1,4</sup>”

Source: [OTEZLA: PsO Efficacy Overview, captured 2026-11-13](https://www.otezlapro.com/plaque-psoriasis/efficacy/#:~:text=SPROUT%20study%20design%3A%20A%20Phase,moderate%20to%20severe%20plaque%20psoriasis.)

> “In SPROUT, 33% (n=163) of patients taking Otezla achieved an sPGA score of 0 (clear) or 1 (almost clear) and a ≥2-point reduction from baseline vs 10.8% placebo (n=82) at week 16 (P<0.0001; primary endpoint) <sup>1,4</sup>”

Source: [OTEZLA: PsO Efficacy Overview, captured 2026-11-13](https://www.otezlapro.com/plaque-psoriasis/efficacy/#:~:text=In%20SPROUT%2C%2033%25%20%28n%3D163%29%20of,week%2016%20%28P%3C0.0001%3B%20primary%20endpoint%29)

> “Table 11. Efficacy Results at Week 16 in Pediatric Subjects 6 to 17 Years of Age and Weighing at 
> Least 20 kg with Moderate to Severe Plaque Psoriasis in Trial PSOR-6 
> Trial PSOR-6 
> Placebo 
> OTEZLA<sup>a</sup>  
> Treatment  
> Difference<sup>b,c</sup> 
> (95% CI)<sup>d</sup> 
> Number of Subjects Randomized 
> N = 82 
> N = 163 
>
> sPGA Response<sup>e</sup> 
> 10.8% 
> 33.1% 
> 22.3%  
> (12.2%, 32.4%) 
> PASI-75 Response<sup>f</sup> 
> 16.0% 
> 45.7% 
> 29.7% 
> (17.9%, 41.6%) 
> <sup>a</sup>  Subjects weighing ≥ 50 kg received OTEZLA 30 mg twice daily and subjects weighing 20 kg to < 50 kg 
> received OTEZLA 20 mg twice daily.”

Source: [OTEZLA: Prescribing information, page 26, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=26)

> “A total of 221 (90.2%) patients completed the double-blind phase and 24 discontinued (Otezla, 14 [8.6%]; placebo, 10 [12.2%]) <sup>1</sup>”

Source: [OTEZLA: SPROUT: Efficacy in Pediatric Patients, captured 2026-11-13](https://www.otezlapro.com/plaque-psoriasis/efficacy/sprout/#:~:text=A%20total%20of%20221%20%2890.2%25%29,14%20%5B8.6%25%5D%3B%20placebo%2C%2010%20%5B12.2%25%5D%29)

Note: Table 11 columns are placebo, OTEZLA, and the treatment difference with its 95% CI. The Prescribing Information names the trial PSOR-6; the Otezla HCP site names it SPROUT.

## Clinical trials

<a id="otezla-psoriasis-trial-enrollment"></a>

### How many adults were in the Otezla ESTEEM and ADVANCE psoriasis trials?

Applies to: Plaque psoriasis in adults who are candidates for phototherapy or systemic therapy

> “ADVANCE was a multicenter, randomized,
> placebo-controlled, double-blind study. Biologic-naïve adults with mild to moderate plaque psoriasis (N=595) were randomized 1:1 to receive Otezla or placebo for a 16-week phase, followed by a 16-week extension phase and a 4-week post-treatment observation phase. <sup>1,3</sup>”

Source: [OTEZLA: Plaque Psoriasis Study Design Overviews, captured 2026-11-13](https://www.otezlapro.com/plaque-psoriasis/study-design/#:~:text=ADVANCE%20was%20a%20multicenter%2C%20randomized%2C,a%204%2Dweek%20post%2Dtreatment%20observation%20phase.)

> “ESTEEM consists of 2 multicenter, double-blind, placebo-controlled trials of similar design. Patients aged ≥18 years with moderate to severe plaque psoriasis (N=1257) were randomized 2:1 to Otezla 30 mg BID (n=836) or placebo (n=419) for 16 weeks after a week-long titration. <sup>1,4,5</sup>”

Source: [OTEZLA: Plaque Psoriasis Study Design Overviews, captured 2026-11-13](https://www.otezlapro.com/plaque-psoriasis/study-design/#:~:text=ESTEEM%20consists%20of%202%20multicenter%2C,weeks%20after%20a%20week%2Dlong%20titration.)

<a id="otezla-psoriasis-trials"></a>

### Which clinical trials studied Otezla for plaque psoriasis?

> “ADVANCE was a multicenter, randomized, placebo-controlled, double-blind study of biologic-naïve adults with mild to moderate plaque psoriasis. <sup>3</sup>”

Source: [OTEZLA: Frequently Asked Questions (FAQs), captured 2026-11-14](https://www.otezlapro.com/resource-center/faqs/#:~:text=ADVANCE%20was%20a%20multicenter%2C%20randomized%2C,mild%20to%20moderate%20plaque%20psoriasis.)

On the page, select: HOW LONG WAS OTEZLA IN CLINICAL TRIALS?

> “ESTEEM 1 and ESTEEM 2 were 2 large, pivotal, Phase 3, randomized, placebo-controlled studies evaluating apremilast in patients with a diagnosis of moderate to severe plaque psoriasis for at least 12 months prior to screening, and who were also candidates for phototherapy and/or systemic therapy. <sup>1-3</sup>”

Source: [OTEZLA: Frequently Asked Questions (FAQs), captured 2026-11-14](https://www.otezlapro.com/resource-center/faqs/#:~:text=ESTEEM%201%20and%20ESTEEM%202%20were,for%20phototherapy%20and%2For%20systemic%20therapy.)

On the page, select: HOW LONG WAS OTEZLA IN CLINICAL TRIALS?

> “LIBERATE was a global, Phase 3b, placebo-controlled, double-blind, double-dummy study that evaluated use of apremilast in biologic-naïve patients with moderate to severe plaque psoriasis for up to 104 weeks. <sup>4</sup>”

Source: [OTEZLA: Frequently Asked Questions (FAQs), captured 2026-11-14](https://www.otezlapro.com/resource-center/faqs/#:~:text=LIBERATE%20was%20a%20global%2C%20Phase,for%20up%20to%20104%20weeks.)

On the page, select: HOW LONG WAS OTEZLA IN CLINICAL TRIALS?

> “STYLE was a Phase 3, multicenter, randomized, double-blind, placebo-controlled study of 303 adult moderate to severe plaque psoriasis patients with moderate to severe plaque psoriasis of the scalp. <sup>6</sup>”

Source: [OTEZLA: Frequently Asked Questions (FAQs), captured 2026-11-14](https://www.otezlapro.com/resource-center/faqs/#:~:text=STYLE%20was%20a%20Phase%203%2C,plaque%20psoriasis%20of%20the%20scalp.)

On the page, select: HOW LONG WAS OTEZLA IN CLINICAL TRIALS?

> “DISCREET was a Phase 3, multicenter, randomized, placebo-controlled, double-blind study of 289 adult patients with moderate to severe plaque psoriasis and moderate to severe plaque psoriasis of the genital area. <sup>3</sup>”

Source: [OTEZLA: Frequently Asked Questions (FAQs), captured 2026-11-14](https://www.otezlapro.com/resource-center/faqs/#:~:text=DISCREET%20was%20a%20Phase%203%2C,psoriasis%20of%20the%20genital%20area.)

On the page, select: HOW LONG WAS OTEZLA IN CLINICAL TRIALS?

> “SPROUT was a Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety of Otezla in 245 pediatric patients whose ages ranged from 6 to 17 years old, with moderate to severe plaque psoriasis. <sup>7</sup>”

Source: [OTEZLA: Frequently Asked Questions (FAQs), captured 2026-11-14](https://www.otezlapro.com/resource-center/faqs/#:~:text=SPROUT%20was%20a%20Phase%203%2C,moderate%20to%20severe%20plaque%20psoriasis.)

On the page, select: HOW LONG WAS OTEZLA IN CLINICAL TRIALS?

Note: The FAQ answer also lists trials in psoriatic arthritis and Behcet's disease, which are not quoted.

## Related pages
- [Medical information: Otezla (apremilast): Plaque psoriasis](https://www.evicenter.com/medical-information/otezla--plaque-psoriasis)
- [Indication](https://www.evicenter.com/medical-information/otezla--plaque-psoriasis/indication)
- [Safety](https://www.evicenter.com/medical-information/otezla--plaque-psoriasis/safety)
- [Specific populations](https://www.evicenter.com/medical-information/otezla--plaque-psoriasis/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/otezla--plaque-psoriasis/dosing-and-administration)
